How genes and blood levels of duloxetine relate to fibromyalgia symptom relief
Studies how genes and duloxetine blood levels relate to symptoms in adults with fibromyalgia.
Key facts
- Who runs it
- University of Utah
- Where
- Salt Lake City, United StatesSee the site
- Trial code
- Registry title
- Duloxetine Metabolism and Fibromyalgia
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 1 May 2025
- Expected to end
- 1 May 2027
- Type of study
- Observational
- Treatments tested
- Observational
- Record updated
- 25 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with fibromyalgia who already take duloxetine. It studies genes, duloxetine blood levels and how well it helps symptoms.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- People who meet the diagnostic criteria for fibromyalgia.
- Earlier treatment
- Must be taking Duloxetine 60 mg/day for at least 8 weeks.
Main reasons for not taking part
- Pregnancy, based on what the person says
- History of kidney or liver problems diagnosed by a doctor, or of kidney dialysis
- Needing an interpreter to communicate
- Other worsening illnesses with chronic pain and tiredness, such as cancer under cancer treatment, Parkinson's disease or Multiple Sclerosis
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adults 18+
- Meeting diagnostic criteria for Fibromyalgia
- Patients taking Duloxetine 60 mg/day for at least 8 weeks
Who cannot take part
- Patient's with progressive illnesses other than fibromyalgia that have a chronic pain and fatigue component (e.g., cancer patients receiving antineoplastic treatment, Parkinson's disease, Multiple Sclerosis)
- Patients that have a history of physician diagnosed kidney or liver disfunction or history of renal dialysis
- Pregnant patients per verbal confirmation
- Patients requiring an interpreter to communicate
Where in United States
- Pain Management Center and Pain Research Center at the University of UtahSalt Lake City, United StatesContact: Jake Steenblick, DNPTaking people
About the trial
What the trial wants to find out
People with fibromyalgia report generalized body pain ("pain all over"), increased sensitivity to painful stimulation, chronic tiredness or low energy, sleep problems, and other physical and functional problems. The exact cause of the disorder is poorly understood, and treatment can be difficult.
Read full original descriptionShow less
The degree to which duloxetine is helpful for people with fibromyalgia varies greatly. For some people, it is very helpful for managing fibromyalgia symptoms. For others, people may not notice any benefit. Yet for some, it is a little helpful and the effect is noticeable only when people forget to take the medicine.
The purpose of this study is to collect data to better understand the relationship among gene types that control those enzymes, blood concentrations of duloxetine, and how it helps the symptoms.
The group in the trial
- Adult patients treated with duloxetine for fibromyalgia
Adults 18+ Meeting diagnostic criteria for Fibromyalgia Patients taking Duloxetine 60 mg/day for at least 8 weeks
Treatment: Observational
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Duloxetine Metabolism and Fibromyalgia
- Plain-language title
- How genes and blood levels of duloxetine relate to fibromyalgia symptom reliefGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 25 September 2026